Figure 6. FAK downregulation after tumor formation using the CK19-CreER^T2 Tamoxifen system inhibits tumor progression.

(A) Study design. (B) Survival analysis of Fak^f/f mice bearing Akt/YAP/CreER^T2 tumors treated with Tamoxifen or vehicle (Control). (C) Liver weight, (D) Gross image, H&E staining, HNF-4α, and CK19 immunohistochemistry of livers from pretreatment, control, and Tamoxifen groups. Arrows indicate tiny lesions consisting of small cell clusters, which were typically conserved in Tamoxifen-treated mice. (E) FAK Western blot analysis was performed in Fak^f/f mice bearing Akt/YAP/CreER^T2 tumors sensitized with Tamoxifen (Group2 in C) or not (Group1 in C). (F) Large areas of necrosis (N) in livers from Group2 mice, as shown at two magnifications. Abbreviations: T, tumor; ST, surrounding tissue.